General Information
Baloxavir Marboxil API is a cap-dependent endonuclease inhibitor that impedes the growth and spread of influenza virus in its finished dose. Baloxavir Marboxil specifically targets and binds to the influenza polymerase acidic (PA) protein, inhibiting its CEN activity. This inhibition of PA endonuclease halts the replication of influenza virus mRNA, resulting in a reduction of viral load. It was approved for medical use both in Japan and in the United States in 2018.
About the API
- Japan DMF
- Korea DMF
- US DMF
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.